Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2025European Journal of Cardio-Thoracic Surgery

Neoadjuvant immuno-chemotherapy versus neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYuxin YangCYChang YuanBLBin Li

Discussion

Loading...

Member takes

Overview

Retrospective analysis compares survival rates and treatment responses in esophageal squamous cell carcinoma, suggesting immunotherapy benefits.

Key Points

  • NICE improved overall survival at 3 years to 73.5%, showing a significant benefit compared to CROSS's 58.4% survival rate.
  • Pathological complete remission rates were similar between the neoadjuvant therapies at 20.9% for NICE and 25.4% for CROSS, with no significant difference.
  • A higher proportion of patients receiving adjuvant therapy after NICE was noted, underscoring immunotherapy's role in long-term outcomes.
  • Significant differences in survival emerged for non-pCR patients, with a hazard ratio of 1.86 favoring the NICE treatment.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/68d46cb831b076d99fa68709https://doi.org/10.1093/ejcts/ezaf302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1780. NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMORADIOTHERAPY VS NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CARCINOMA (CSTAGEII-III): A MULTI-CENTER PROSPECTIVE RANDOMIZED CLINICAL TRIAL (ICROSS)2024
  2. 2Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study2025 · 6 citations
  3. 3Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma2024 · 6 citations
  4. 4Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemoradiotherapy versus Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Real-World, Three-Arm, Retrospective Cohort Study from the Chinese National Cancer Center2026
  5. 5A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐<scp>5FU</scp> and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study2024 · 1 citations